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1. INTRODUCTION {#cam42757-sec-0001}
===============

T‐cell acute lymphoblastic leukemia (ALL)/lymphoma is an uncommon disease in adults and more aggressive than the more common pediatric counterpart.[1](#cam42757-bib-0001){ref-type="ref"} T‐ALL in adults, however, is potentially curable with 50% of 5‐year survival rate.[2](#cam42757-bib-0002){ref-type="ref"} Chromosomal translocations occur in a subset T‐ALL cases; these translocations often involve the T‐cell receptor gene loci or *KMT2A* with variable partner genes, including *TAL1*, *TAL2*, *TLX1*, *TLX3*, *HOXA*, *LMO1*, *LMO2*, and *NKX2*.[3](#cam42757-bib-0003){ref-type="ref"}, [4](#cam42757-bib-0004){ref-type="ref"}, [5](#cam42757-bib-0005){ref-type="ref"}, [6](#cam42757-bib-0006){ref-type="ref"}, [7](#cam42757-bib-0007){ref-type="ref"} Several genes involving various cellular signaling pathways are also recurrently mutated in T‐ALL. Examples of these mutations are *PTEN* mutation/deletion in PI3K‐AKT pathway and *N/KRAS* mutations in MAPK‐ERK signaling pathway.[8](#cam42757-bib-0008){ref-type="ref"}, [9](#cam42757-bib-0009){ref-type="ref"}, [10](#cam42757-bib-0010){ref-type="ref"} Activation of NOTCH1 pathway is also a hallmark of both pediatric and adult T‐ALL implicating a favorable outcome.[11](#cam42757-bib-0011){ref-type="ref"}, [12](#cam42757-bib-0012){ref-type="ref"}, [13](#cam42757-bib-0013){ref-type="ref"} In most instances NOTCH1 activation results from activating mutations in *NOTCH1* but in fewer cases loss‐of‐function mutations in *FBXW7*, an inhibitor of *NOTCH1*, lead to constitutive NOTCH1 overexpression.[14](#cam42757-bib-0014){ref-type="ref"}, [15](#cam42757-bib-0015){ref-type="ref"} Various combinations of common gene alterations in T‐ALL have been associated with different responses to therapy and different clinical outcomes.[8](#cam42757-bib-0008){ref-type="ref"}, [16](#cam42757-bib-0016){ref-type="ref"}, [17](#cam42757-bib-0017){ref-type="ref"}, [18](#cam42757-bib-0018){ref-type="ref"}, [19](#cam42757-bib-0019){ref-type="ref"}

The overall outcome in adult T‐ALL has improved over the past several decades, largely due to better risk stratification and intensified chemotherapeutic regimens.[20](#cam42757-bib-0020){ref-type="ref"}, [21](#cam42757-bib-0021){ref-type="ref"}, [22](#cam42757-bib-0022){ref-type="ref"} Major prognostically important clinical factors in T‐ALL patient are age at diagnosis, peripheral blood (PB) count (tumor burden), maturational stage of neoplastic cells and CNS involvement.[2](#cam42757-bib-0002){ref-type="ref"}, [23](#cam42757-bib-0023){ref-type="ref"} Status of minimal residual disease (MRD) is considered the single most influential factor in predicting long‐term survival after induction therapy.[24](#cam42757-bib-0024){ref-type="ref"}, [25](#cam42757-bib-0025){ref-type="ref"}, [26](#cam42757-bib-0026){ref-type="ref"}, [27](#cam42757-bib-0027){ref-type="ref"}, [28](#cam42757-bib-0028){ref-type="ref"}

Several large scale studies have shown clinically relevant genetic changes in both pediatric and adult T‐ALL.[9](#cam42757-bib-0009){ref-type="ref"}, [11](#cam42757-bib-0011){ref-type="ref"}, [18](#cam42757-bib-0018){ref-type="ref"}, [19](#cam42757-bib-0019){ref-type="ref"}, [29](#cam42757-bib-0029){ref-type="ref"}, [30](#cam42757-bib-0030){ref-type="ref"}, [31](#cam42757-bib-0031){ref-type="ref"} Trinquand et al suggested that a *NOTCH1/FBXW7/RAS/PTEN*‐based classifier predicts relapse‐free survival (RFS) and overall survival (OS) in adults with T‐ALL.[29](#cam42757-bib-0029){ref-type="ref"} The utility of this approach was further confirmed in children with T‐ALL.[32](#cam42757-bib-0032){ref-type="ref"}, [33](#cam42757-bib-0033){ref-type="ref"} In this model, T‐ALL with mutations in *NOTCH1/FBXW7* (*N/F*) without any changes in either *(K/N)RAS* or *PTEN* (*R/P*) is considered a genetically low‐risk group, whereas all other combinations of these gene mutations were considered genetically high‐risk.[29](#cam42757-bib-0029){ref-type="ref"} The induction chemotherapeutic regimen used in previous studies for this oncogenetic classifier consisted of vincristine, daunorubicin, L‐asparaginase, and cyclophosphamide (Berlin‐Frankfurt‐Münster \[BFM\] protocol).[29](#cam42757-bib-0029){ref-type="ref"}, [33](#cam42757-bib-0033){ref-type="ref"} The standard treatment regimen for adults with T‐ALL at our institution, however, is *h*yper‐fractionated *c*yclophosphamide, *v*incristine, *d*oxorubicin and *d*examethasone (hyper‐CVAD) with or without nelarabine (<https://clinicaltrials.gov/ct2/show/NCT00501826)>.[34](#cam42757-bib-0034){ref-type="ref"} The reproducibility of (*N/F/R/P*) risk stratification model in adult T‐ALL patients treated with hyper‐CVAD ± nelarabine has not been evaluated. In this study, we assessed the applicability of this model in our cohort of adults with T‐ALL treated with hyper‐CVAD ± nelarabine.

2. MATERIALS AND METHODS {#cam42757-sec-0002}
========================

2.1. Patients {#cam42757-sec-0003}
-------------

We searched the electronic medical record to identify adult patients with T‐ALL in the bone marrow (BM) between 2012 and 2018. Inclusion criteria included: (a) patients ≥18 years; (b) those who were treatment‐naïve at time of first presentation to our institution; (c) patients treated with hyper‐CVAD ± nelarabine; and (d) next‐generation sequencing (NGS)‐based mutation analysis was performed. Exclusion criteria included: (a) blast crisis of chronic myeloid leukemia with T‐lymphoblasts; (b) mixed phenotype acute leukemia; (c) patients with nodal or extranodal involvement by T‐lymphoblastic lymphoma with minimal (≤5% blasts) BM involvement.

The clinicopathologic, cytogenetic and mutational data on patients in the study were collected by reviewing patients' electronic medical records. Complete remission (CR) or CR with incomplete hematologic recovery (CRi) were assessed according to the latest national comprehensive cancer network clinical practice guidelines.[35](#cam42757-bib-0035){ref-type="ref"} Qualitative polymerase chain reaction‐based methods were performed using genomic DNA (gDNA) extracted from BM aspirate specimens to assess for rearrangements of *TRG* and *TRB*.[36](#cam42757-bib-0036){ref-type="ref"} Measurable MRD was analyzed by multiparameter flow cytometry (MFC) analyses (assay has been validated to a sensitivity of 0.1%‐0.01%). This study was approved by the institutional Review Board at The University of Texas MD Anderson Cancer Center and performed in accord with the Declaration of Helsinki.

2.2. NGS analysis {#cam42757-sec-0004}
-----------------

Next‐generation sequencing‐based mutation analysis was performed using previously described 28‐gene or 81‐gene panels (complete list of the genes in Table [S1](#cam42757-sup-0002){ref-type="supplementary-material"}).[37](#cam42757-bib-0037){ref-type="ref"} Briefly, sequencing libraries were prepared from 250 ng of gDNA using HaloPlex Target Enrichment Kit (Agilent Technologies) and sequencing libraries were subject to a MiSeq sequencer (Illumina). NGS data analysis was performed using SureCall (Haloplex). The Integrative Genomics Viewer (IGV; Broad Institute) was used to visualize read alignment and confirm variant calls.[38](#cam42757-bib-0038){ref-type="ref"} A custom‐developed, in‐house software package (OncoSeek) was used to annotate sequence variants and to interface the data with the IGV. Nomenclature of genetic variants was designated following the Human Genome Variation Society recommendations.[39](#cam42757-bib-0039){ref-type="ref"} The limit of detection of the NGS assays was 1%.

2.3. Statistical analysis {#cam42757-sec-0005}
-------------------------

Overall survival was defined from the time of diagnosis to death from any cause. RFS and time to relapse were defined as the time from diagnosis or remission (CR/CRi) to first outcome event (induction failure, death during remission, or relapse), respectively. Patients who underwent stem cell transplant were censored. Statistical analysis was performed using GraphPad Prism 7 (GraphPad Software, Inc) and IBM^®^ SPSS Statistics 24 (IBM, Inc). Fisher\'s exact test and Mann‐Whitney *U* test were used to assess categorical and continuous variables, respectively. Survival probability was determined using the Kaplan‐Meier method, with difference compared by the log‐rank test. A Cox proportional‐hazards model was used for univariate and multivariate analysis. A *P*‐value (two‐sided) under .05 was considered statistically significant.

3. RESULTS {#cam42757-sec-0006}
==========

3.1. Patient characteristics {#cam42757-sec-0007}
----------------------------

The study cohort includes 27 patients, 23 men and 4 women, with the median age at diagnosis of 37 years (range: 18‐75 years) (Table [1](#cam42757-tbl-0001){ref-type="table"}). The median hemoglobin level was 10.3 g/dL (range: 5.8‐16.9 g/dL); leukocyte count 14.5 × 10^9^/L (range: 1‐137 × 10^9^/L), and platelet count 123 × 10^9^/L (range: 13‐327 × 10^9^/L). The median blast count was 80% (range: 6%‐96%) and 61% (range: 0%‐100%) in BM and PB, respectively. Immunophenotype included early T‐cell precursor (n = 9), double negative (n = 8), double positive (n = 4), and single positive (n = 6).

###### 

Clinical and laboratory characteristics of patient cohort

  Feature                                     T‐cell acute lymphoblastic leukemia                                       
  ------------------------------------------- ------------------------------------- ----------------- ----------------- -----
  Gender                                                                                                                
  Male                                        23                                    18                7                 .57
  Female                                      4                                     2                 2                 
  Median age (y) (range)                      37 (18‐75)                            42 (20‐70)        26 (18‐75)        .56
  White blood cell count (×10^9^/L) (range)   14.5 (1‐137)                          28.5 (2‐108)      9.3 (1‐137)       .77
  Platelet (×10^3^/µL) (range)                123 (13‐327)                          177.5 (13‐327)    53 (13‐203)       .06
  Hg (g/dL) (range)                           10.3 (5.8‐16.9)                       10.4 (5.8‐16.9)   10.2 (7.6‐15.4)   .80
  Blast % (range)                                                                                                       
  Bone marrow                                 80 (6‐96)                             75.5 (6‐94)       82 (45‐96)        .19
  Peripheral blood                            61 (0‐100)                            65.5 (0‐100)      32 (0‐90)         .63
  Cytogenetic (n = 25)                                                                                                  
  Normal                                      12                                    8                 4                 .99
  Simple                                      4                                     3                 1                 
  Complex                                     9                                     6                 3                 
  TR gene subsets                                                                                                       
  Gamma only                                  5                                     4                 1                 .99
  Beta                                        14                                    8                 6                 
  Germline                                    6                                     4                 2                 
  3‐y overall survival                        50%                                   72%               36%               .02
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Conventional cytogenetic analysis was available in 25 patients. These included 12 patients with normal karyotype, 4 with a simple abnormality (\<3 abnormalities), and 9 with a complex karyotype (≥3 abnormalities). Well‐known translocations involving T‐cell receptor gene loci, t(10;11)(p13;q14), or t(11;19)(q23;p13) were not present. Monoclonal T‐cell receptor gene rearrangements (*TRG* and/or *TRB*) were detected in 19 (76%) patients. All patients were treated with the standard chemotherapy regimen of hyper‐CVAD (n = 6) or hyper‐CVAD + nelarabine (n = 21).

3.2. High rate of complete remission (CR/CRi) after hyper‐CVAD ± nelarabine regimen {#cam42757-sec-0008}
-----------------------------------------------------------------------------------

Twenty‐six (96%) patients achieved CR/CRi after the first or second course of induction chemotherapy. Eight of 26 (31%) patients relapsed at a median interval of 9.3 months (range: 3.2‐18.2 months) after remission. With a median follow‐up of 22.6 months (range: 3.8‐49.7 months), 15 (65%) patients were alive and the 3‐year OS rate was 50%. The median OS was 32.6 months.

3.3. Commonly mutated genes in T‐ALL {#cam42757-sec-0009}
------------------------------------

Twenty‐six (96%) patients had mutations in at least one of the tested gene. Fourteen (52%) patients showed a total of 19 *NOTCH1* mutations. Recurrent hotspot mutations were not seen in *NOTCH1*. The median mutant allelic frequency (MAF) was 29% (range: 2.3%‐53.5%) indicating a heterozygous change in most cases. Six patients had *NOTCH1* mutation with a MAF \< 10%. Three of these patients had other major mutant clones in *NOTCH* 1 (patients \#2 and 4) and *TP53* (patient \#7), respectively. *NOTCH1* mutation was the only mutation in the remaining three patients (patients \#8, 10, and 12) who had 81%, 32%, and 24% blasts in bone marrow, respectively.

Other recurrently mutated genes in this cohort were *NRAS* (n = 6), *DNMT3A* (n = 5), *KRAS* (n = 4) and *TP53* (n = 2) (Table [2](#cam42757-tbl-0002){ref-type="table"}). The median MAF of the *NRAS* mutations was 37.8% (range: 3.6%‐48.2%). Two patients had *NRAS* mutation with a MAF \< 10%; both had major mutant clones in *NOTCH1* (patients \#2 and 4). Five of 6 patients with *NRAS* mutation also had a *NOTCH1* mutation. The median MAF of *DNMT3A* mutation was 41.5% (range: 2.6%‐49.8%). None of the 5 patients with *DNMT3A* mutation had a *NOTCH1* mutation. *KRAS* mutations were mostly subclonal (median MAF: 5.5%) and 2 of 4 *KRAS*‐mutated patients with MAF \< 10% had mutations in other genes. In contrast, *TP53* mutations were major clones (MAF: 93.5% and 25.4%). The two patients with *TP53* mutation also had *NOTCH1* mutation. Mutations in *FBXW7* and *PTEN* were not detected in the study cohort.

###### 

Most commonly mutated genes in our patient cohort at the time of diagnosis. The mutant allele frequency (MAF) of mutated genes is indicated inside the corresponding box

  Gene       Pt.ID                                                                                                                                                                            
  ---------- ------- ---------- ------ ---------- ------ ----------- ------ ----- ------ ----- ------- ----- ------ ------ --------- ----- ------ ----- ------ ------ --- --- --- --- --- --- ---
  *NOTCH1*   32.1    38.1/5.3   53.5   35.9/2.3   38.3   48.3/42.4   4.4    9.1   13.3   6.6   46/29   5.5   23.4   23.3                                                                       
  *NRAS*     18.2    4.5        48.2   37.8/3.6   46.3                                                                     39.3                                                                
  *KRAS*     9.4     40.9                                                                                                  1.7       1.2                                                       
  *DNMT3A*                                                                                                                 46/41.7         19.2   2.6   41.2   49.8                            
  *TP53*                                                 93.8        25.4                                                                                                                      
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3.4. N/F/R/P binary risk model did not stratify T‐ALL patients treated with hyper‐CVAD‐based regimen {#cam42757-sec-0010}
----------------------------------------------------------------------------------------------------

As a single mutation, no significant differences in outcome were observed in patients with *NOTCH1*, *NRAS*, or *DNMT3A* mutation (Figure [1](#cam42757-fig-0001){ref-type="fig"}A‐F). However, patients with *TP53* mutation had a poor outcome (Figure [1](#cam42757-fig-0001){ref-type="fig"}G,H). Meanwhile, the N/F/R/P binary risk model suggested by Trinquand et al[29](#cam42757-bib-0029){ref-type="ref"} failed to adequately stratify the patients in this cohort (Figure [2](#cam42757-fig-0002){ref-type="fig"}A,B). We further analyzed survival outcome of 4 groups in this cohort based on the mutational status of *NOTCH1* and *RAS*, which did not demonstrate satisfactory risk stratification (Figure [2](#cam42757-fig-0002){ref-type="fig"}C). In the patient group with wild‐type *NOTCH1*, the presence of *RAS* mutation predicted a poorer prognosis (*P* = .01). In the group with *NOTCH1* mutation, however, outcome was similar irrespective of *RAS* mutation (*P* = .93). Given the fact that *TP53* mutation was co‐mutated with *NOTCH1*, we re‐classified the group based on *NOTCH1* and *RAS*/*TP53* mutations. The new 4‐group risk model showed improved stratification in outcome (Figure [2](#cam42757-fig-0002){ref-type="fig"}D). Since *NOTCH1* mutation did not show much difference in *RAS*/*TP53* wild‐type group and mutated patient groups, we further simplified stratification of patients into 2 groups based on *RAS*/*TP53* mutation irrespective of *NOTCH1* status (low‐risk \[n = 18\]: *RAS* and *TP53* wild‐type, high‐risk \[n = 9\]: *RAS* or *TP53* mutated, hereafter will be referred to MDACC risk groups). This new risk model showed significant risk stratification in both OS (*P* = .03) and RFS (*P* = .04) (Figure [2](#cam42757-fig-0002){ref-type="fig"}E,F).

![Probability of OS and RFS in our patient cohort based on multiple single gene mutations at the time of diagnosis. A and B, OS and RFS regarding *NOTCH1* mutation. C and D, OS and RFS regarding *K/RAS* mutation. E and F, OS and RFS regarding *DNMT3A*mutation. G and H, OS and RFS regarding regarding *TP53*mutation. Only a mutated *TP53* showed a significant effect on both OS and RFS. mut, mutated; OS, overall survival; RFS, relapse free survival; wt, wildtype](CAM4-9-849-g001){#cam42757-fig-0001}

![Probability of OS and RFS in our patient cohort based on different combinations of gene mutations at the time of diagnosis. A and B, Low‐risk and high‐risk groups were determined according to the NFRP model (low risk: *NOTCH1/FBXW7* mutated and *RAS/PTEN* wildtype and; high risk: *RAS* or *PTEN* mutated). C, Different combinations of *NOTCH1* and *(N/K)RAS* mutations. D, Different combinations of *NOTCH1* and combined (*RAS* or *TP53*) gene mutations. E and F, Low‐risk and high‐risk groups were determined according to the MDACC model (low risk: *RAS* or *TP53* wild‐type; high risk: *RAS* and/or *TP53* mutation). MDACC, MD Anderson Cancer Center; mut, mutated; NFRP, *NOTCH*, *FBXW7*, *RAS*, *PTEN*; OS, overall survival; R/T, *RAS* or *TP53*; RFS, relapse free survival; wt, wildtype](CAM4-9-849-g002){#cam42757-fig-0002}

3.5. End‐of‐induction measurable residual disease (MRD) by flow cytometry did not predict patient outcome {#cam42757-sec-0011}
---------------------------------------------------------------------------------------------------------

The status of MRD was assessed with MFC at the end of first and/or second induction in all but one patient who had refractory disease. Eighteen (69%) and 8 (31%) patients showed a positive and negative MRD at the end of induction chemotherapy. The status of MRD by MFC did not demonstrate significant difference in survival (Figure [3](#cam42757-fig-0003){ref-type="fig"}A,B). MDACC risk model further separated two prognostically different groups both in patients with positive MRD (*P* = .02), but not in those with negative MRD (*P* = .23) (Figure [3](#cam42757-fig-0003){ref-type="fig"}C,D).

![A and B, OS and RFS for patients with T‐ALL based on measurable MRD in all patients. C and D, OS in patients with a positive (C) or a negative (D) MRD at the end of induction chemotherapy stratified based on MDACC risk classifier. MDACC, MD Anderson Cancer Center; MRD, minimal residual disease; OS, overall survival; RFS, relapse free survival; T‐ALL, T‐cell acute lymphoblastic leukemia](CAM4-9-849-g003){#cam42757-fig-0003}

3.6. Low white blood cell counts are associated with poor OS in T‐ALL {#cam42757-sec-0012}
---------------------------------------------------------------------

Prognostic impact of white blood cell count (WBC) is less firmly established for adult T‐ALL than for the pediatric T‐ALL. High WBC of ≥100 × 10^9^/L, however, is commonly considered a high‐risk factor for both adult and pediatric T‐ALL.[35](#cam42757-bib-0035){ref-type="ref"} In our cohort the median WBC was 14.5 × 10^9^/L (range: 1‐137 × 10^9^/L) and only two patients (\# 6 and 26) had WBC \> 100 × 10^9^/L at the time of diagnosis. Due to the skewed distribution to the lower WBC (\<100 × 10^9^/L), we performed an ROC curve calculation to select a cutoff of WBC for which the difference in survival is more significant. The WBC of 10.8 × 10^9^/L shows the best discrimination. Based on the new discriminator, patients with WBC of \<10.8 × 10^9^/L (n = 9) had worse outcome compared with those with higher WBC (≥10.8 × 10^9^/L) (n = 18) (median OS: 14.6 months and not reached, respectively, *P* = .02; median RFS: 13 months and not reached, respectively, *P* = .12) (Figure [4](#cam42757-fig-0004){ref-type="fig"}A,B). Similar to the above subgroup analysis with respect to MRD status, MDACC risk model further separated two prognostically different groups both in patients with WBC of \<10.8 × 10^9^/L (*P* = .02), but not in those with WBC of ≥10.8 × 10^9^/L (*P* = .77) (Figure [4](#cam42757-fig-0004){ref-type="fig"}C,D).

![A and B, OS and RFS for patients with T‐ALL based on WBC count at the time of diagnosis in all patients. C and D, OS in patients with a high \[≥10.8 × 10^9^/L\] (C) or low \[\<10.8 × 10^9^/L\] (D) WBC at the end of induction chemotherapy stratified based on MDACC risk classifier. MDACC, MD Anderson Cancer Center; OS, overall survival; RFS, relapse free survival; T‐ALL, T‐cell acute lymphoblastic leukemia; WBC, white blood cell](CAM4-9-849-g004){#cam42757-fig-0004}

3.7. MDACC risk stratification is an independent factor predicting worse OS in adult T‐ALL patients treated with the hyper‐CVAD {#cam42757-sec-0013}
-------------------------------------------------------------------------------------------------------------------------------

In univariate analysis, both MDACC high risk and lower WBC had increased risk of death. MRD status did not show any statistically significant difference. In multivariate analysis, MDACC risk model remained to have an increased risk of death (hazard ratio; 4.9, 95% confidence interval; 1.213‐19.621, *P* = .026) (Table [3](#cam42757-tbl-0003){ref-type="table"}).

###### 

Specific hazard ratios (HR) calculated in univariate and multivariate analysis of three major factors of MDACC risk stratification (MDACC), white blood cells counts (WBC), and measurable residual disease (MRD) historically important in prognosis of T acute lymphoblastic leukemia for overall survival (OS)

  Variable   Univariate analysis   Multivariate analysis                                 
  ---------- --------------------- ----------------------- ------ ------- -------------- ------
  MDACC      3.663                 1.027‐13.070            .045   4.878   1.213‐19.621   .026
  WBC        4.13                  1.121‐15.219            .033   3.992   1.002‐15.903   .050
  MRD        1.62                  0.343‐7.637             .542   3.068   0.596‐15.798   .180
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4. DISCUSSION {#cam42757-sec-0014}
=============

In this study, we have examined a relatively small cohort of uniformly treated adult T‐ALL patients for whom a systematic mutation analysis for the most relevant genes in T‐ALL were performed at the time of diagnosis and before the initiation of induction therapy. While studying such a homogenous group of patients from a rare entity such as T‐ALL is valuable, it should be clarified that the outcome of the study is considered preliminary due to low number of patients in the cohort.

The mutational profile of adult T‐ALL in our cohort is similar to that reported in the literature.[14](#cam42757-bib-0014){ref-type="ref"}, [40](#cam42757-bib-0040){ref-type="ref"} Almost all patients in our cohort had a mutation(s) in at least one gene. *NOTCH1* was the most common gene mutation, in over half of cases, followed by *KRAS/NRAS* and *DNMT3A* mutations in 26%, and 19%, respectively. *NOTCH1* mutations were usually a major clone (MAF ≥ 10%), but subclonal fraction (MAF \< 10%) was not uncommon. *NRAS* mutation (22%) was more common than *KRAS* mutation (15%), but co‐mutations in both *NRAS* and *KRAS* were found in 50% and 75% of *NRAS*‐ and *KRAS*‐mutated T‐ALL cases. Unlike other studies, *DNMT3A* mutation was mutually exclusive to *NOTCH1* mutation in this cohort.[41](#cam42757-bib-0041){ref-type="ref"} *TP53* mutation was rare in this study (2/27, 7%) which is similar to the frequencies identified in previous studies with much larger cohort of adult T‐ALL patients (between 5% and 11%).[42](#cam42757-bib-0042){ref-type="ref"}, [43](#cam42757-bib-0043){ref-type="ref"} We did not observe any alterations in the *FBXW7* and *PTEN* genes.

*NOTCH1* mutation has been associated with a favorable outcome in most of earlier studies.[11](#cam42757-bib-0011){ref-type="ref"}, [12](#cam42757-bib-0012){ref-type="ref"}, [13](#cam42757-bib-0013){ref-type="ref"}, [14](#cam42757-bib-0014){ref-type="ref"} However, in this study we did not observe a favorable outcome for patients with *NOTCH1* mutation (Figure [1](#cam42757-fig-0001){ref-type="fig"}A,B). We also analyzed patients with a major *NOTCH1* mutant clone (MAF \> 10%), but a favorable outcome was not observed (data now shown). As the presence of mutations in *TP53* [42](#cam42757-bib-0042){ref-type="ref"}, [43](#cam42757-bib-0043){ref-type="ref"} or *RAS* [17](#cam42757-bib-0017){ref-type="ref"} at the time of diagnosis of T‐ALL have been reported to be correlated with an unfavorable outcome, and seven of 14 *NOTCH1*‐mutated patients also had mutations of *K/NRAS* or *TP53*, we speculated that this unexpected negative result may be due to presence of the co‐mutation. Nevertheless, exclusion of *TP53*‐ or *K/NRAS*‐mutated cases did not reveal any favorable outcome for *NOTCH1* mutated cases (data not shown). Similarly, *RAS* mutation was not associated with a poorer outcome in our cohort (Figure [1](#cam42757-fig-0001){ref-type="fig"}C,D), which showed prognosis in other studies.[17](#cam42757-bib-0017){ref-type="ref"}, [44](#cam42757-bib-0044){ref-type="ref"} Furthermore, when we applied the N/F/R/P classifier, we did not observe any prognostic discrimination in our cohort (Figure [2](#cam42757-fig-0002){ref-type="fig"}A,B). However, when we divided our patients into 4 groups based on wild‐type or mutated *NOTCH1* and *RAS*, it did not show satisfactory stratification (*P* = .1) (Figure [2](#cam42757-fig-0002){ref-type="fig"}C). Focusing on the *NOTCH1* wild‐type subgroup, the presence of a *RAS* mutation showed a poorer prognosis (*P* = .01). However, in the *NOTCH1*‐mutated subgroup, outcome was similar irrespective of *RAS* mutation (*P* = .93). We noticed that *TP53*‐mutated patients in our cohort also had co‐mutation in *NOTCH1*. We hypothesized that *TP53* mutation could have negative effect on survival in *NOTCH1*‐mutated patients, and re‐classified our cohort based on *NOTCH1* and *RAS/TP53* mutation. This approach demonstrated improved risk stratification (*P* = .05) (Figure [2](#cam42757-fig-0002){ref-type="fig"}D). In this stratification model, *NOTCH1* mutation did not further stratify patients in *RAS*/*TP53*‐mutated (*P* = .89) and *RAS*/*TP53* wild‐type groups (*P* = .17). Therefore, we further simplified the risk model using only *RAS* and *TP53* mutation (low risk: *RAS* and *TP53* wild type, high risk: *RAS* or *TP53* mutation), which showed improved risk stratification compared to the N/F/R/P model.

The N/F/R/P classifier failed to stratify T‐ALL patients in our cohort. Presumably, the main reason is due to the fact that *NOTCH1* mutation was not associated with favorable outcome in our cohort. Although reasons are unclear, the prognostic effect of *NOTCH1* mutation in T‐ALL might not be significant if patients are treated with non‐BFM protocols. Indeed, lack of favorable outcome for *NOTCH1* mutation in T‐ALL has been reported, particularly in studies treated with regimens other than BFM‐ALL protocols.[45](#cam42757-bib-0045){ref-type="ref"}, [46](#cam42757-bib-0046){ref-type="ref"}, [47](#cam42757-bib-0047){ref-type="ref"}, [48](#cam42757-bib-0048){ref-type="ref"} Enrichment of ETP (33%) in our cohort could be attributable to the negative impact of *NOTCH1* mutation since it is well‐known for worse clinical outcome.[49](#cam42757-bib-0049){ref-type="ref"}, [50](#cam42757-bib-0050){ref-type="ref"} However, to the best of our knowledge, it is unknown if N/F/R/P classifier retains prognostic power after stratified by immunophenotype. Cytogenetic aberrations do not seem to affect the result since our cohort demonstrates similar cytogenetic profile to previous studies.[49](#cam42757-bib-0049){ref-type="ref"}, [51](#cam42757-bib-0051){ref-type="ref"} Instead, *RAS* and *TP53* mutation could be the most significant factor for risk stratification.

Measurable residual disease status measured by flow cytometry after induction chemotherapy was not correlated with outcome in our cohort. However, application of our molecular risk model further identified patients with higher risk, showing the utility of our model. We found an inverse association between white blood cell count and outcome in adult T‐ALL. Patients who had WBC of \<10.8 × 10^9^/L showed a significantly poorer OS compared to patient with higher WBC. Similar to MRD status, our molecular risk model further discriminated patients with WBC of \<10.8 × 10^9^/L. In univariate analysis, both MDACC molecular risk model and WBC count were significant risk factors but the former remains significant in multivariate analysis.

In summary, the N/F/R/P molecular classifier at diagnosis cannot be applied to adult T‐ALL patients treated with hyper‐CVAD with or without nelarabine. Instead, we found that *RAS* and *TP53* mutations (MDACC risk model) showed improved stratification in adult T‐ALL patients. The poor outcome of *TP53* mutated T‐ALL is in contrast to a recent report showed lack of the MDACC risk model was an independent risk factor in multivariate analysis. A larger, independent study is needed to confirm out data.

CONFLICT OF INTEREST {#cam42757-sec-0015}
====================

All authors have nothing to disclose.

Supporting information
======================

###### 

 

###### 

Click here for additional data file.

###### 

 

###### 

Click here for additional data file.
